Kailera Therapeutics is a clinical-stage biotech focused on obesity medicines built around GLP-1-based mechanisms. Its pipeline spans injectable and oral candidates, including dual- and multi-agonist approaches intended for people at different points in weight-management care. With little to no commercial revenue yet, the story centers on clinical development rather than marketed products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -18 | — |
| Q2 2025 | 0 | — | -28.9 | — |
| Q1 2026 | 0 | — | -78.9 | — |
| Q2 2026 | 0 | — | -111.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Pacira BioSciences, Inc. (PCRX), Healthcare Services Group, Inc. (HCSG), MillerKnoll, Inc. (MLKN), United Fire Group, Inc. (UFCS), Lakeland Financial Corporation (LKFN), Quantum Computing Inc. (QUBT)